nodes	percent_of_prediction	percent_of_DWPC	metapath
Naloxone—TLR4—ovarian cancer	0.414	0.714	CbGaD
Naloxone—ESR1—ovarian cancer	0.116	0.2	CbGaD
Naloxone—SLCO1A2—Chlorambucil—ovarian cancer	0.115	0.504	CbGbCtD
Naloxone—ABCB1—ovarian cancer	0.0493	0.0851	CbGaD
Naloxone—ABCB1—Topotecan—ovarian cancer	0.0215	0.0945	CbGbCtD
Naloxone—CYP2C8—Paclitaxel—ovarian cancer	0.0157	0.0691	CbGbCtD
Naloxone—ABCB1—Vinorelbine—ovarian cancer	0.0152	0.0666	CbGbCtD
Naloxone—CYP3A4—Topotecan—ovarian cancer	0.0129	0.0566	CbGbCtD
Naloxone—ABCB1—Paclitaxel—ovarian cancer	0.0107	0.0468	CbGbCtD
Naloxone—CYP3A4—Vinorelbine—ovarian cancer	0.00908	0.0399	CbGbCtD
Naloxone—ABCB1—Docetaxel—ovarian cancer	0.0077	0.0338	CbGbCtD
Naloxone—CYP3A4—Paclitaxel—ovarian cancer	0.00638	0.028	CbGbCtD
Naloxone—ABCB1—Doxorubicin—ovarian cancer	0.00574	0.0252	CbGbCtD
Naloxone—ESR1—ovarian follicle—ovarian cancer	0.00511	0.1	CbGeAlD
Naloxone—CYP3A4—Docetaxel—ovarian cancer	0.00461	0.0203	CbGbCtD
Naloxone—CYP3A4—Doxorubicin—ovarian cancer	0.00344	0.0151	CbGbCtD
Naloxone—TLR4—decidua—ovarian cancer	0.00307	0.0603	CbGeAlD
Naloxone—TLR4—endometrium—ovarian cancer	0.00292	0.0573	CbGeAlD
Naloxone—TLR4—bone marrow—ovarian cancer	0.00228	0.0448	CbGeAlD
Naloxone—ESR1—oviduct—ovarian cancer	0.00224	0.0441	CbGeAlD
Naloxone—TLR4—female gonad—ovarian cancer	0.0022	0.0432	CbGeAlD
Naloxone—TLR4—testis—ovarian cancer	0.00195	0.0383	CbGeAlD
Naloxone—CREB1—myometrium—ovarian cancer	0.00182	0.0358	CbGeAlD
Naloxone—CREB1—embryo—ovarian cancer	0.00175	0.0344	CbGeAlD
Naloxone—CREB1—epithelium—ovarian cancer	0.00143	0.0281	CbGeAlD
Naloxone—CREB1—uterine cervix—ovarian cancer	0.00142	0.0279	CbGeAlD
Naloxone—TLR4—lymph node—ovarian cancer	0.00141	0.0277	CbGeAlD
Naloxone—CREB1—decidua—ovarian cancer	0.00135	0.0266	CbGeAlD
Naloxone—Ache—Vinorelbine—ovarian cancer	0.00133	0.0314	CcSEcCtD
Naloxone—CREB1—endometrium—ovarian cancer	0.00128	0.0252	CbGeAlD
Naloxone—CREB1—gonad—ovarian cancer	0.00119	0.0234	CbGeAlD
Naloxone—CREB1—uterus—ovarian cancer	0.00118	0.0232	CbGeAlD
Naloxone—CREB1—female reproductive system—ovarian cancer	0.00106	0.0209	CbGeAlD
Naloxone—CREB1—bone marrow—ovarian cancer	0.001	0.0197	CbGeAlD
Naloxone—CREB1—female gonad—ovarian cancer	0.000967	0.019	CbGeAlD
Naloxone—CREB1—vagina—ovarian cancer	0.000961	0.0189	CbGeAlD
Naloxone—Grand mal convulsion—Paclitaxel—ovarian cancer	0.000867	0.0205	CcSEcCtD
Naloxone—Convulsion—Altretamine—ovarian cancer	0.000858	0.0203	CcSEcCtD
Naloxone—CREB1—testis—ovarian cancer	0.000858	0.0169	CbGeAlD
Naloxone—OPRK1—female reproductive system—ovarian cancer	0.000806	0.0158	CbGeAlD
Naloxone—ESR1—myometrium—ovarian cancer	0.000718	0.0141	CbGeAlD
Naloxone—Injection site reaction—Melphalan—ovarian cancer	0.000698	0.0165	CcSEcCtD
Naloxone—ESR1—embryo—ovarian cancer	0.00069	0.0136	CbGeAlD
Naloxone—Encephalopathy—Paclitaxel—ovarian cancer	0.000643	0.0152	CcSEcCtD
Naloxone—CREB1—lymph node—ovarian cancer	0.000622	0.0122	CbGeAlD
Naloxone—Injection site reaction—Vinorelbine—ovarian cancer	0.00061	0.0144	CcSEcCtD
Naloxone—Asthenia—Altretamine—ovarian cancer	0.00058	0.0137	CcSEcCtD
Naloxone—ESR1—epithelium—ovarian cancer	0.000563	0.0111	CbGeAlD
Naloxone—ESR1—uterine cervix—ovarian cancer	0.000559	0.011	CbGeAlD
Naloxone—Pulmonary oedema—Vinorelbine—ovarian cancer	0.000546	0.0129	CcSEcCtD
Naloxone—ESR1—decidua—ovarian cancer	0.000532	0.0105	CbGeAlD
Naloxone—Vomiting—Altretamine—ovarian cancer	0.000514	0.0122	CcSEcCtD
Naloxone—Rhinorrhoea—Paclitaxel—ovarian cancer	0.000509	0.012	CcSEcCtD
Naloxone—ESR1—endometrium—ovarian cancer	0.000505	0.00992	CbGeAlD
Naloxone—Cardiac arrest—Topotecan—ovarian cancer	0.000495	0.0117	CcSEcCtD
Naloxone—Cardiac arrest—Melphalan—ovarian cancer	0.000485	0.0115	CcSEcCtD
Naloxone—Nausea—Altretamine—ovarian cancer	0.00048	0.0114	CcSEcCtD
Naloxone—Pain—Carboplatin—ovarian cancer	0.000478	0.0113	CcSEcCtD
Naloxone—ESR1—gonad—ovarian cancer	0.000469	0.0092	CbGeAlD
Naloxone—ESR1—uterus—ovarian cancer	0.000465	0.00914	CbGeAlD
Naloxone—OPRM1—testis—ovarian cancer	0.000463	0.00909	CbGeAlD
Naloxone—Body temperature increased—Carboplatin—ovarian cancer	0.000442	0.0104	CcSEcCtD
Naloxone—Rhinorrhoea—Docetaxel—ovarian cancer	0.000432	0.0102	CcSEcCtD
Naloxone—ESR1—female reproductive system—ovarian cancer	0.000418	0.00822	CbGeAlD
Naloxone—CYP2C8—endometrium—ovarian cancer	0.000416	0.00817	CbGeAlD
Naloxone—Ventricular tachycardia—Paclitaxel—ovarian cancer	0.000413	0.00975	CcSEcCtD
Naloxone—Injection site reaction—Paclitaxel—ovarian cancer	0.00041	0.0097	CcSEcCtD
Naloxone—Hallucination—Chlorambucil—ovarian cancer	0.000402	0.00951	CcSEcCtD
Naloxone—SLCO1A2—testis—ovarian cancer	0.000398	0.00782	CbGeAlD
Naloxone—ALB—testis—ovarian cancer	0.000396	0.00778	CbGeAlD
Naloxone—Sweating—Topotecan—ovarian cancer	0.000385	0.00909	CcSEcCtD
Naloxone—ESR1—female gonad—ovarian cancer	0.000381	0.00748	CbGeAlD
Naloxone—ESR1—vagina—ovarian cancer	0.000378	0.00743	CbGeAlD
Naloxone—Injection site reaction—Docetaxel—ovarian cancer	0.000348	0.00822	CcSEcCtD
Naloxone—CYP2C8—female reproductive system—ovarian cancer	0.000345	0.00677	CbGeAlD
Naloxone—ESR1—testis—ovarian cancer	0.000338	0.00663	CbGeAlD
Naloxone—Tremor—Chlorambucil—ovarian cancer	0.00033	0.0078	CcSEcCtD
Naloxone—Flushing—Melphalan—ovarian cancer	0.000327	0.00773	CcSEcCtD
Naloxone—Angiopathy—Topotecan—ovarian cancer	0.000327	0.00772	CcSEcCtD
Naloxone—Mediastinal disorder—Topotecan—ovarian cancer	0.000325	0.00767	CcSEcCtD
Naloxone—Agitation—Chlorambucil—ovarian cancer	0.000324	0.00765	CcSEcCtD
Naloxone—Chills—Topotecan—ovarian cancer	0.000323	0.00764	CcSEcCtD
Naloxone—Hot flush—Paclitaxel—ovarian cancer	0.00032	0.00757	CcSEcCtD
Naloxone—Mediastinal disorder—Melphalan—ovarian cancer	0.000318	0.00751	CcSEcCtD
Naloxone—Menopausal symptoms—Paclitaxel—ovarian cancer	0.000317	0.0075	CcSEcCtD
Naloxone—CYP2C8—vagina—ovarian cancer	0.000312	0.00612	CbGeAlD
Naloxone—Pulmonary oedema—Docetaxel—ovarian cancer	0.000311	0.00736	CcSEcCtD
Naloxone—Convulsion—Chlorambucil—ovarian cancer	0.000305	0.00721	CcSEcCtD
Naloxone—ALB—lymph node—ovarian cancer	0.000287	0.00564	CbGeAlD
Naloxone—Cardiac disorder—Vinorelbine—ovarian cancer	0.000286	0.00676	CcSEcCtD
Naloxone—Flushing—Vinorelbine—ovarian cancer	0.000286	0.00676	CcSEcCtD
Naloxone—Cardiac arrest—Paclitaxel—ovarian cancer	0.000285	0.00673	CcSEcCtD
Naloxone—ABCB1—myometrium—ovarian cancer	0.000283	0.00557	CbGeAlD
Naloxone—Angiopathy—Vinorelbine—ovarian cancer	0.000279	0.00661	CcSEcCtD
Naloxone—CYP2C8—testis—ovarian cancer	0.000278	0.00546	CbGeAlD
Naloxone—Mediastinal disorder—Vinorelbine—ovarian cancer	0.000278	0.00656	CcSEcCtD
Naloxone—ABCB1—embryo—ovarian cancer	0.000273	0.00536	CbGeAlD
Naloxone—Hot flush—Docetaxel—ovarian cancer	0.000271	0.00641	CcSEcCtD
Naloxone—Menopausal symptoms—Docetaxel—ovarian cancer	0.000269	0.00636	CcSEcCtD
Naloxone—Nasopharyngitis—Paclitaxel—ovarian cancer	0.000268	0.00633	CcSEcCtD
Naloxone—Convulsion—Melphalan—ovarian cancer	0.000266	0.00629	CcSEcCtD
Naloxone—Unspecified disorder of skin and subcutaneous tissue—Topotecan—ovarian cancer	0.000265	0.00626	CcSEcCtD
Naloxone—Unspecified disorder of skin and subcutaneous tissue—Melphalan—ovarian cancer	0.000259	0.00613	CcSEcCtD
Naloxone—Nervous system disorder—Topotecan—ovarian cancer	0.000251	0.00593	CcSEcCtD
Naloxone—Skin disorder—Topotecan—ovarian cancer	0.000248	0.00587	CcSEcCtD
Naloxone—Gastrointestinal disorder—Chlorambucil—ovarian cancer	0.000248	0.00586	CcSEcCtD
Naloxone—Hyperhidrosis—Topotecan—ovarian cancer	0.000247	0.00585	CcSEcCtD
Naloxone—Pain—Chlorambucil—ovarian cancer	0.000246	0.00581	CcSEcCtD
Naloxone—ESR1—lymph node—ovarian cancer	0.000245	0.00481	CbGeAlD
Naloxone—Tachycardia—Melphalan—ovarian cancer	0.000244	0.00578	CcSEcCtD
Naloxone—Skin disorder—Melphalan—ovarian cancer	0.000243	0.00575	CcSEcCtD
Naloxone—Ventricular tachycardia—Epirubicin—ovarian cancer	0.000236	0.00558	CcSEcCtD
Naloxone—Injection site reaction—Epirubicin—ovarian cancer	0.000234	0.00554	CcSEcCtD
Naloxone—CYP3A4—female reproductive system—ovarian cancer	0.000233	0.00459	CbGeAlD
Naloxone—Hypertension—Vinorelbine—ovarian cancer	0.000232	0.00547	CcSEcCtD
Naloxone—Depression—Paclitaxel—ovarian cancer	0.00023	0.00544	CcSEcCtD
Naloxone—Paraesthesia—Topotecan—ovarian cancer	0.00023	0.00543	CcSEcCtD
Naloxone—Dyspnoea—Topotecan—ovarian cancer	0.000228	0.00539	CcSEcCtD
Naloxone—Abdominal pain—Chlorambucil—ovarian cancer	0.000227	0.00537	CcSEcCtD
Naloxone—Body temperature increased—Chlorambucil—ovarian cancer	0.000227	0.00537	CcSEcCtD
Naloxone—Nasopharyngitis—Docetaxel—ovarian cancer	0.000227	0.00537	CcSEcCtD
Naloxone—Unspecified disorder of skin and subcutaneous tissue—Vinorelbine—ovarian cancer	0.000227	0.00536	CcSEcCtD
Naloxone—Paraesthesia—Melphalan—ovarian cancer	0.000225	0.00532	CcSEcCtD
Naloxone—Dyspnoea—Melphalan—ovarian cancer	0.000223	0.00528	CcSEcCtD
Naloxone—ABCB1—epithelium—ovarian cancer	0.000222	0.00437	CbGeAlD
Naloxone—Gastrointestinal disorder—Topotecan—ovarian cancer	0.000221	0.00522	CcSEcCtD
Naloxone—ABCB1—uterine cervix—ovarian cancer	0.000221	0.00433	CbGeAlD
Naloxone—Pain—Topotecan—ovarian cancer	0.000219	0.00517	CcSEcCtD
Naloxone—Ventricular tachycardia—Doxorubicin—ovarian cancer	0.000218	0.00516	CcSEcCtD
Naloxone—Injection site reaction—Doxorubicin—ovarian cancer	0.000217	0.00513	CcSEcCtD
Naloxone—Gastrointestinal disorder—Melphalan—ovarian cancer	0.000216	0.00511	CcSEcCtD
Naloxone—Coma—Epirubicin—ovarian cancer	0.000216	0.00509	CcSEcCtD
Naloxone—Nervous system disorder—Vinorelbine—ovarian cancer	0.000215	0.00507	CcSEcCtD
Naloxone—Pain—Melphalan—ovarian cancer	0.000214	0.00506	CcSEcCtD
Naloxone—Tachycardia—Vinorelbine—ovarian cancer	0.000214	0.00505	CcSEcCtD
Naloxone—Skin disorder—Vinorelbine—ovarian cancer	0.000213	0.00502	CcSEcCtD
Naloxone—ABCB1—decidua—ovarian cancer	0.00021	0.00413	CbGeAlD
Naloxone—Pulmonary oedema—Epirubicin—ovarian cancer	0.00021	0.00496	CcSEcCtD
Naloxone—Asthenia—Chlorambucil—ovarian cancer	0.000206	0.00487	CcSEcCtD
Naloxone—Abdominal pain—Topotecan—ovarian cancer	0.000202	0.00478	CcSEcCtD
Naloxone—Body temperature increased—Topotecan—ovarian cancer	0.000202	0.00478	CcSEcCtD
Naloxone—ABCB1—endometrium—ovarian cancer	0.0002	0.00392	CbGeAlD
Naloxone—Coma—Doxorubicin—ovarian cancer	0.000199	0.00471	CcSEcCtD
Naloxone—Diarrhoea—Chlorambucil—ovarian cancer	0.000197	0.00465	CcSEcCtD
Naloxone—Paraesthesia—Vinorelbine—ovarian cancer	0.000197	0.00465	CcSEcCtD
Naloxone—Dyspnoea—Vinorelbine—ovarian cancer	0.000195	0.00461	CcSEcCtD
Naloxone—Pulmonary oedema—Doxorubicin—ovarian cancer	0.000194	0.00459	CcSEcCtD
Naloxone—Cardiac disorder—Paclitaxel—ovarian cancer	0.000192	0.00455	CcSEcCtD
Naloxone—Flushing—Paclitaxel—ovarian cancer	0.000192	0.00455	CcSEcCtD
Naloxone—Gastrointestinal disorder—Vinorelbine—ovarian cancer	0.000189	0.00447	CcSEcCtD
Naloxone—Angiopathy—Paclitaxel—ovarian cancer	0.000188	0.00444	CcSEcCtD
Naloxone—Pain—Vinorelbine—ovarian cancer	0.000187	0.00442	CcSEcCtD
Naloxone—Mediastinal disorder—Paclitaxel—ovarian cancer	0.000187	0.00441	CcSEcCtD
Naloxone—Chills—Paclitaxel—ovarian cancer	0.000186	0.00439	CcSEcCtD
Naloxone—ABCB1—gonad—ovarian cancer	0.000185	0.00364	CbGeAlD
Naloxone—ABCB1—uterus—ovarian cancer	0.000184	0.00361	CbGeAlD
Naloxone—Asthenia—Topotecan—ovarian cancer	0.000184	0.00434	CcSEcCtD
Naloxone—Hot flush—Epirubicin—ovarian cancer	0.000183	0.00433	CcSEcCtD
Naloxone—Vomiting—Chlorambucil—ovarian cancer	0.000183	0.00432	CcSEcCtD
Naloxone—Mental disorder—Paclitaxel—ovarian cancer	0.000182	0.00429	CcSEcCtD
Naloxone—Menopausal symptoms—Epirubicin—ovarian cancer	0.000181	0.00429	CcSEcCtD
Naloxone—Asthenia—Melphalan—ovarian cancer	0.00018	0.00425	CcSEcCtD
Naloxone—Tension—Paclitaxel—ovarian cancer	0.000177	0.00418	CcSEcCtD
Naloxone—Nervousness—Paclitaxel—ovarian cancer	0.000175	0.00414	CcSEcCtD
Naloxone—Diarrhoea—Topotecan—ovarian cancer	0.000175	0.00414	CcSEcCtD
Naloxone—Abdominal pain—Vinorelbine—ovarian cancer	0.000173	0.00409	CcSEcCtD
Naloxone—Body temperature increased—Vinorelbine—ovarian cancer	0.000173	0.00409	CcSEcCtD
Naloxone—Diarrhoea—Melphalan—ovarian cancer	0.000171	0.00405	CcSEcCtD
Naloxone—Nausea—Chlorambucil—ovarian cancer	0.000171	0.00403	CcSEcCtD
Naloxone—Hot flush—Doxorubicin—ovarian cancer	0.000169	0.004	CcSEcCtD
Naloxone—Tremor—Paclitaxel—ovarian cancer	0.000169	0.00399	CcSEcCtD
Naloxone—Menopausal symptoms—Doxorubicin—ovarian cancer	0.000168	0.00397	CcSEcCtD
Naloxone—Agitation—Paclitaxel—ovarian cancer	0.000166	0.00392	CcSEcCtD
Naloxone—ABCB1—female reproductive system—ovarian cancer	0.000165	0.00325	CbGeAlD
Naloxone—Flushing—Docetaxel—ovarian cancer	0.000163	0.00385	CcSEcCtD
Naloxone—Cardiac disorder—Docetaxel—ovarian cancer	0.000163	0.00385	CcSEcCtD
Naloxone—Cardiac arrest—Epirubicin—ovarian cancer	0.000163	0.00385	CcSEcCtD
Naloxone—Vomiting—Topotecan—ovarian cancer	0.000163	0.00384	CcSEcCtD
Naloxone—Angiopathy—Docetaxel—ovarian cancer	0.000159	0.00377	CcSEcCtD
Naloxone—Vomiting—Melphalan—ovarian cancer	0.000159	0.00376	CcSEcCtD
Naloxone—Mediastinal disorder—Docetaxel—ovarian cancer	0.000158	0.00374	CcSEcCtD
Naloxone—Chills—Docetaxel—ovarian cancer	0.000158	0.00372	CcSEcCtD
Naloxone—Asthenia—Vinorelbine—ovarian cancer	0.000157	0.00371	CcSEcCtD
Naloxone—Convulsion—Paclitaxel—ovarian cancer	0.000156	0.00369	CcSEcCtD
Naloxone—ABCB1—bone marrow—ovarian cancer	0.000156	0.00307	CbGeAlD
Naloxone—Hypertension—Paclitaxel—ovarian cancer	0.000156	0.00368	CcSEcCtD
Naloxone—Mental disorder—Docetaxel—ovarian cancer	0.000154	0.00364	CcSEcCtD
Naloxone—Nasopharyngitis—Epirubicin—ovarian cancer	0.000153	0.00362	CcSEcCtD
Naloxone—Unspecified disorder of skin and subcutaneous tissue—Paclitaxel—ovarian cancer	0.000152	0.0036	CcSEcCtD
Naloxone—Nausea—Topotecan—ovarian cancer	0.000152	0.00359	CcSEcCtD
Naloxone—Cardiac arrest—Doxorubicin—ovarian cancer	0.000151	0.00356	CcSEcCtD
Naloxone—ABCB1—female gonad—ovarian cancer	0.00015	0.00295	CbGeAlD
Naloxone—Diarrhoea—Vinorelbine—ovarian cancer	0.00015	0.00354	CcSEcCtD
Naloxone—ABCB1—vagina—ovarian cancer	0.000149	0.00294	CbGeAlD
Naloxone—Nausea—Melphalan—ovarian cancer	0.000149	0.00352	CcSEcCtD
Naloxone—Nervous system disorder—Paclitaxel—ovarian cancer	0.000144	0.00341	CcSEcCtD
Naloxone—Tachycardia—Paclitaxel—ovarian cancer	0.000144	0.0034	CcSEcCtD
Naloxone—Skin disorder—Paclitaxel—ovarian cancer	0.000143	0.00338	CcSEcCtD
Naloxone—Hyperhidrosis—Paclitaxel—ovarian cancer	0.000142	0.00336	CcSEcCtD
Naloxone—Nasopharyngitis—Doxorubicin—ovarian cancer	0.000142	0.00335	CcSEcCtD
Naloxone—Vomiting—Vinorelbine—ovarian cancer	0.000139	0.00329	CcSEcCtD
Naloxone—ABCB1—testis—ovarian cancer	0.000133	0.00262	CbGeAlD
Naloxone—Convulsion—Docetaxel—ovarian cancer	0.000132	0.00313	CcSEcCtD
Naloxone—Paraesthesia—Paclitaxel—ovarian cancer	0.000132	0.00312	CcSEcCtD
Naloxone—Hypertension—Docetaxel—ovarian cancer	0.000132	0.00312	CcSEcCtD
Naloxone—Dyspnoea—Paclitaxel—ovarian cancer	0.000131	0.0031	CcSEcCtD
Naloxone—Nausea—Vinorelbine—ovarian cancer	0.00013	0.00307	CcSEcCtD
Naloxone—Unspecified disorder of skin and subcutaneous tissue—Docetaxel—ovarian cancer	0.000129	0.00306	CcSEcCtD
Naloxone—Gastrointestinal disorder—Paclitaxel—ovarian cancer	0.000127	0.003	CcSEcCtD
Naloxone—Sweating—Epirubicin—ovarian cancer	0.000126	0.00299	CcSEcCtD
Naloxone—Pain—Paclitaxel—ovarian cancer	0.000126	0.00298	CcSEcCtD
Naloxone—Nervous system disorder—Docetaxel—ovarian cancer	0.000122	0.00289	CcSEcCtD
Naloxone—Tachycardia—Docetaxel—ovarian cancer	0.000122	0.00288	CcSEcCtD
Naloxone—Skin disorder—Docetaxel—ovarian cancer	0.000121	0.00286	CcSEcCtD
Naloxone—Sweating—Doxorubicin—ovarian cancer	0.000117	0.00277	CcSEcCtD
Naloxone—Abdominal pain—Paclitaxel—ovarian cancer	0.000116	0.00275	CcSEcCtD
Naloxone—Body temperature increased—Paclitaxel—ovarian cancer	0.000116	0.00275	CcSEcCtD
Naloxone—Paraesthesia—Docetaxel—ovarian cancer	0.000112	0.00265	CcSEcCtD
Naloxone—Dyspnoea—Docetaxel—ovarian cancer	0.000111	0.00263	CcSEcCtD
Naloxone—Cardiac disorder—Epirubicin—ovarian cancer	0.00011	0.0026	CcSEcCtD
Naloxone—Flushing—Epirubicin—ovarian cancer	0.00011	0.0026	CcSEcCtD
Naloxone—Gastrointestinal disorder—Docetaxel—ovarian cancer	0.000108	0.00255	CcSEcCtD
Naloxone—Angiopathy—Epirubicin—ovarian cancer	0.000107	0.00254	CcSEcCtD
Naloxone—Mediastinal disorder—Epirubicin—ovarian cancer	0.000107	0.00252	CcSEcCtD
Naloxone—Pain—Docetaxel—ovarian cancer	0.000107	0.00252	CcSEcCtD
Naloxone—Chills—Epirubicin—ovarian cancer	0.000106	0.00251	CcSEcCtD
Naloxone—Asthenia—Paclitaxel—ovarian cancer	0.000106	0.0025	CcSEcCtD
Naloxone—Mental disorder—Epirubicin—ovarian cancer	0.000104	0.00245	CcSEcCtD
Naloxone—Cardiac disorder—Doxorubicin—ovarian cancer	0.000102	0.0024	CcSEcCtD
Naloxone—Flushing—Doxorubicin—ovarian cancer	0.000102	0.0024	CcSEcCtD
Naloxone—Tension—Epirubicin—ovarian cancer	0.000101	0.00239	CcSEcCtD
Naloxone—Diarrhoea—Paclitaxel—ovarian cancer	0.000101	0.00238	CcSEcCtD
Naloxone—Nervousness—Epirubicin—ovarian cancer	0.0001	0.00237	CcSEcCtD
Naloxone—Angiopathy—Doxorubicin—ovarian cancer	9.94e-05	0.00235	CcSEcCtD
Naloxone—Mediastinal disorder—Doxorubicin—ovarian cancer	9.88e-05	0.00233	CcSEcCtD
Naloxone—Body temperature increased—Docetaxel—ovarian cancer	9.86e-05	0.00233	CcSEcCtD
Naloxone—Abdominal pain—Docetaxel—ovarian cancer	9.86e-05	0.00233	CcSEcCtD
Naloxone—Chills—Doxorubicin—ovarian cancer	9.83e-05	0.00232	CcSEcCtD
Naloxone—ABCB1—lymph node—ovarian cancer	9.67e-05	0.0019	CbGeAlD
Naloxone—Mental disorder—Doxorubicin—ovarian cancer	9.6e-05	0.00227	CcSEcCtD
Naloxone—Agitation—Epirubicin—ovarian cancer	9.48e-05	0.00224	CcSEcCtD
Naloxone—Tension—Doxorubicin—ovarian cancer	9.36e-05	0.00221	CcSEcCtD
Naloxone—Vomiting—Paclitaxel—ovarian cancer	9.36e-05	0.00221	CcSEcCtD
Naloxone—Nervousness—Doxorubicin—ovarian cancer	9.27e-05	0.00219	CcSEcCtD
Naloxone—Asthenia—Docetaxel—ovarian cancer	8.95e-05	0.00212	CcSEcCtD
Naloxone—Convulsion—Epirubicin—ovarian cancer	8.93e-05	0.00211	CcSEcCtD
Naloxone—Hypertension—Epirubicin—ovarian cancer	8.9e-05	0.0021	CcSEcCtD
Naloxone—Agitation—Doxorubicin—ovarian cancer	8.77e-05	0.00207	CcSEcCtD
Naloxone—Nausea—Paclitaxel—ovarian cancer	8.74e-05	0.00207	CcSEcCtD
Naloxone—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—ovarian cancer	8.72e-05	0.00206	CcSEcCtD
Naloxone—Diarrhoea—Docetaxel—ovarian cancer	8.54e-05	0.00202	CcSEcCtD
Naloxone—Convulsion—Doxorubicin—ovarian cancer	8.27e-05	0.00195	CcSEcCtD
Naloxone—Nervous system disorder—Epirubicin—ovarian cancer	8.25e-05	0.00195	CcSEcCtD
Naloxone—Hypertension—Doxorubicin—ovarian cancer	8.24e-05	0.00195	CcSEcCtD
Naloxone—Tachycardia—Epirubicin—ovarian cancer	8.21e-05	0.00194	CcSEcCtD
Naloxone—Skin disorder—Epirubicin—ovarian cancer	8.17e-05	0.00193	CcSEcCtD
Naloxone—Hyperhidrosis—Epirubicin—ovarian cancer	8.14e-05	0.00192	CcSEcCtD
Naloxone—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—ovarian cancer	8.07e-05	0.00191	CcSEcCtD
Naloxone—Vomiting—Docetaxel—ovarian cancer	7.93e-05	0.00188	CcSEcCtD
Naloxone—Nervous system disorder—Doxorubicin—ovarian cancer	7.64e-05	0.00181	CcSEcCtD
Naloxone—Tachycardia—Doxorubicin—ovarian cancer	7.6e-05	0.0018	CcSEcCtD
Naloxone—Skin disorder—Doxorubicin—ovarian cancer	7.56e-05	0.00179	CcSEcCtD
Naloxone—Paraesthesia—Epirubicin—ovarian cancer	7.56e-05	0.00179	CcSEcCtD
Naloxone—Hyperhidrosis—Doxorubicin—ovarian cancer	7.53e-05	0.00178	CcSEcCtD
Naloxone—Dyspnoea—Epirubicin—ovarian cancer	7.5e-05	0.00177	CcSEcCtD
Naloxone—Nausea—Docetaxel—ovarian cancer	7.41e-05	0.00175	CcSEcCtD
Naloxone—Gastrointestinal disorder—Epirubicin—ovarian cancer	7.27e-05	0.00172	CcSEcCtD
Naloxone—Pain—Epirubicin—ovarian cancer	7.2e-05	0.0017	CcSEcCtD
Naloxone—Naltrexone—ABCB1—ovarian cancer	7.03e-05	0.425	CrCbGaD
Naloxone—Paraesthesia—Doxorubicin—ovarian cancer	6.99e-05	0.00165	CcSEcCtD
Naloxone—Dyspnoea—Doxorubicin—ovarian cancer	6.94e-05	0.00164	CcSEcCtD
Naloxone—Gastrointestinal disorder—Doxorubicin—ovarian cancer	6.72e-05	0.00159	CcSEcCtD
Naloxone—Pain—Doxorubicin—ovarian cancer	6.66e-05	0.00157	CcSEcCtD
Naloxone—Abdominal pain—Epirubicin—ovarian cancer	6.65e-05	0.00157	CcSEcCtD
Naloxone—Body temperature increased—Epirubicin—ovarian cancer	6.65e-05	0.00157	CcSEcCtD
Naloxone—Body temperature increased—Doxorubicin—ovarian cancer	6.16e-05	0.00145	CcSEcCtD
Naloxone—Abdominal pain—Doxorubicin—ovarian cancer	6.16e-05	0.00145	CcSEcCtD
Naloxone—Asthenia—Epirubicin—ovarian cancer	6.04e-05	0.00143	CcSEcCtD
Naloxone—Diarrhoea—Epirubicin—ovarian cancer	5.76e-05	0.00136	CcSEcCtD
Naloxone—Asthenia—Doxorubicin—ovarian cancer	5.59e-05	0.00132	CcSEcCtD
Naloxone—Vomiting—Epirubicin—ovarian cancer	5.35e-05	0.00126	CcSEcCtD
Naloxone—Diarrhoea—Doxorubicin—ovarian cancer	5.33e-05	0.00126	CcSEcCtD
Naloxone—Buprenorphine—ABCB1—ovarian cancer	5.16e-05	0.313	CrCbGaD
Naloxone—Nausea—Epirubicin—ovarian cancer	5e-05	0.00118	CcSEcCtD
Naloxone—Vomiting—Doxorubicin—ovarian cancer	4.95e-05	0.00117	CcSEcCtD
Naloxone—Nausea—Doxorubicin—ovarian cancer	4.63e-05	0.00109	CcSEcCtD
Naloxone—Morphine—ABCB1—ovarian cancer	4.33e-05	0.262	CrCbGaD
Naloxone—ALB—Metabolism—SLC2A1—ovarian cancer	5.76e-06	5.78e-05	CbGpPWpGaD
Naloxone—ALB—Hemostasis—IL2—ovarian cancer	5.69e-06	5.71e-05	CbGpPWpGaD
Naloxone—CYP2C8—Metabolism of lipids and lipoproteins—PIK3CB—ovarian cancer	5.67e-06	5.69e-05	CbGpPWpGaD
Naloxone—ALB—Metabolism of lipids and lipoproteins—PIK3CB—ovarian cancer	5.64e-06	5.66e-05	CbGpPWpGaD
Naloxone—OPRM1—Signaling Pathways—CAV1—ovarian cancer	5.62e-06	5.64e-05	CbGpPWpGaD
Naloxone—CREB1—Disease—MAPK3—ovarian cancer	5.6e-06	5.62e-05	CbGpPWpGaD
Naloxone—CYP2C8—Metabolism—CYP1B1—ovarian cancer	5.56e-06	5.57e-05	CbGpPWpGaD
Naloxone—ALB—Metabolism—CYP1B1—ovarian cancer	5.52e-06	5.54e-05	CbGpPWpGaD
Naloxone—OPRK1—Signaling by GPCR—MAPK1—ovarian cancer	5.52e-06	5.54e-05	CbGpPWpGaD
Naloxone—OPRK1—Signaling by GPCR—EGFR—ovarian cancer	5.52e-06	5.54e-05	CbGpPWpGaD
Naloxone—CREB1—Signaling by GPCR—PIK3CA—ovarian cancer	5.48e-06	5.5e-05	CbGpPWpGaD
Naloxone—OPRD1—Signaling by GPCR—PIK3CA—ovarian cancer	5.46e-06	5.48e-05	CbGpPWpGaD
Naloxone—CREB1—Immune System—KRAS—ovarian cancer	5.45e-06	5.47e-05	CbGpPWpGaD
Naloxone—CREB1—Disease—MYC—ovarian cancer	5.45e-06	5.47e-05	CbGpPWpGaD
Naloxone—OPRM1—Signaling Pathways—ESR1—ovarian cancer	5.42e-06	5.44e-05	CbGpPWpGaD
Naloxone—ESR1—Signaling Pathways—TERT—ovarian cancer	5.39e-06	5.41e-05	CbGpPWpGaD
Naloxone—CREB1—Signaling Pathways—ERBB2—ovarian cancer	5.38e-06	5.4e-05	CbGpPWpGaD
Naloxone—OPRD1—Signaling Pathways—ERBB2—ovarian cancer	5.37e-06	5.38e-05	CbGpPWpGaD
Naloxone—OPRM1—Signaling Pathways—IL6ST—ovarian cancer	5.33e-06	5.35e-05	CbGpPWpGaD
Naloxone—CREB1—Disease—MAPK1—ovarian cancer	5.33e-06	5.35e-05	CbGpPWpGaD
Naloxone—CREB1—Disease—EGFR—ovarian cancer	5.33e-06	5.35e-05	CbGpPWpGaD
Naloxone—OPRK1—Signaling Pathways—PIK3CD—ovarian cancer	5.33e-06	5.34e-05	CbGpPWpGaD
Naloxone—ABCB1—Metabolism—FASN—ovarian cancer	5.31e-06	5.33e-05	CbGpPWpGaD
Naloxone—CREB1—Signaling Pathways—PIK3CB—ovarian cancer	5.31e-06	5.33e-05	CbGpPWpGaD
Naloxone—CREB1—Signaling Pathways—MTOR—ovarian cancer	5.31e-06	5.33e-05	CbGpPWpGaD
Naloxone—OPRD1—Signaling Pathways—PIK3CB—ovarian cancer	5.3e-06	5.31e-05	CbGpPWpGaD
Naloxone—OPRD1—Signaling Pathways—MTOR—ovarian cancer	5.3e-06	5.31e-05	CbGpPWpGaD
Naloxone—OPRK1—GPCR downstream signaling—PIK3CA—ovarian cancer	5.28e-06	5.29e-05	CbGpPWpGaD
Naloxone—ABCB1—Metabolism—SLC5A5—ovarian cancer	5.23e-06	5.24e-05	CbGpPWpGaD
Naloxone—OPRK1—Signaling by GPCR—KRAS—ovarian cancer	5.22e-06	5.23e-05	CbGpPWpGaD
Naloxone—SLCO1A2—Metabolism—PIK3CB—ovarian cancer	5.14e-06	5.16e-05	CbGpPWpGaD
Naloxone—OPRM1—Signaling Pathways—APC—ovarian cancer	5.12e-06	5.14e-05	CbGpPWpGaD
Naloxone—OPRM1—Signaling Pathways—PIK3CG—ovarian cancer	5.12e-06	5.14e-05	CbGpPWpGaD
Naloxone—OPRM1—Signaling by GPCR—NRAS—ovarian cancer	5.12e-06	5.14e-05	CbGpPWpGaD
Naloxone—CREB1—Signaling Pathways—CXCL8—ovarian cancer	5.11e-06	5.12e-05	CbGpPWpGaD
Naloxone—OPRD1—Signaling Pathways—CXCL8—ovarian cancer	5.09e-06	5.11e-05	CbGpPWpGaD
Naloxone—CREB1—Signaling by GPCR—HRAS—ovarian cancer	5.07e-06	5.09e-05	CbGpPWpGaD
Naloxone—OPRD1—Signaling by GPCR—HRAS—ovarian cancer	5.06e-06	5.07e-05	CbGpPWpGaD
Naloxone—ABCB1—Metabolism—SLC2A1—ovarian cancer	5.05e-06	5.07e-05	CbGpPWpGaD
Naloxone—CREB1—Disease—KRAS—ovarian cancer	5.03e-06	5.05e-05	CbGpPWpGaD
Naloxone—CREB1—Immune System—PIK3CA—ovarian cancer	5.01e-06	5.03e-05	CbGpPWpGaD
Naloxone—CREB1—Signaling Pathways—CDKN1B—ovarian cancer	4.99e-06	5e-05	CbGpPWpGaD
Naloxone—ESR1—Signaling Pathways—CAV1—ovarian cancer	4.99e-06	5e-05	CbGpPWpGaD
Naloxone—OPRD1—Signaling Pathways—CDKN1B—ovarian cancer	4.97e-06	4.99e-05	CbGpPWpGaD
Naloxone—CYP2C8—Metabolism—PPP2R1A—ovarian cancer	4.93e-06	4.94e-05	CbGpPWpGaD
Naloxone—OPRD1—GPCR downstream signaling—AKT1—ovarian cancer	4.92e-06	4.93e-05	CbGpPWpGaD
Naloxone—OPRM1—Signaling by GPCR—MAPK3—ovarian cancer	4.9e-06	4.92e-05	CbGpPWpGaD
Naloxone—CYP2C8—Metabolism of lipids and lipoproteins—PTEN—ovarian cancer	4.9e-06	4.92e-05	CbGpPWpGaD
Naloxone—ALB—Metabolism—PPP2R1A—ovarian cancer	4.9e-06	4.92e-05	CbGpPWpGaD
Naloxone—CREB1—Signaling Pathways—CASP3—ovarian cancer	4.89e-06	4.9e-05	CbGpPWpGaD
Naloxone—CREB1—Signaling Pathways—IL2—ovarian cancer	4.88e-06	4.89e-05	CbGpPWpGaD
Naloxone—ALB—Metabolism of lipids and lipoproteins—PTEN—ovarian cancer	4.88e-06	4.89e-05	CbGpPWpGaD
Naloxone—OPRD1—Signaling Pathways—CASP3—ovarian cancer	4.87e-06	4.89e-05	CbGpPWpGaD
Naloxone—OPRD1—Signaling Pathways—IL2—ovarian cancer	4.86e-06	4.88e-05	CbGpPWpGaD
Naloxone—CREB1—Signaling by GPCR—IL6—ovarian cancer	4.85e-06	4.87e-05	CbGpPWpGaD
Naloxone—ABCB1—Metabolism—CYP1B1—ovarian cancer	4.84e-06	4.86e-05	CbGpPWpGaD
Naloxone—OPRD1—Signaling by GPCR—IL6—ovarian cancer	4.84e-06	4.85e-05	CbGpPWpGaD
Naloxone—ALB—Hemostasis—VEGFA—ovarian cancer	4.84e-06	4.85e-05	CbGpPWpGaD
Naloxone—OPRK1—Signaling by GPCR—PIK3CA—ovarian cancer	4.79e-06	4.81e-05	CbGpPWpGaD
Naloxone—ALB—Hemostasis—NRAS—ovarian cancer	4.78e-06	4.79e-05	CbGpPWpGaD
Naloxone—CREB1—Signaling Pathways—CCND1—ovarian cancer	4.76e-06	4.77e-05	CbGpPWpGaD
Naloxone—OPRD1—Signaling Pathways—CCND1—ovarian cancer	4.74e-06	4.76e-05	CbGpPWpGaD
Naloxone—ESR1—Signaling Pathways—IL6ST—ovarian cancer	4.73e-06	4.74e-05	CbGpPWpGaD
Naloxone—CREB1—Signaling Pathways—CTNNB1—ovarian cancer	4.71e-06	4.72e-05	CbGpPWpGaD
Naloxone—OPRK1—Signaling Pathways—ERBB2—ovarian cancer	4.71e-06	4.72e-05	CbGpPWpGaD
Naloxone—OPRD1—Signaling Pathways—CTNNB1—ovarian cancer	4.69e-06	4.71e-05	CbGpPWpGaD
Naloxone—OPRM1—Signaling by GPCR—MAPK1—ovarian cancer	4.67e-06	4.68e-05	CbGpPWpGaD
Naloxone—OPRM1—Signaling by GPCR—EGFR—ovarian cancer	4.67e-06	4.68e-05	CbGpPWpGaD
Naloxone—OPRK1—Signaling Pathways—PIK3CB—ovarian cancer	4.64e-06	4.66e-05	CbGpPWpGaD
Naloxone—OPRK1—Signaling Pathways—MTOR—ovarian cancer	4.64e-06	4.66e-05	CbGpPWpGaD
Naloxone—CREB1—Immune System—HRAS—ovarian cancer	4.63e-06	4.65e-05	CbGpPWpGaD
Naloxone—CREB1—Disease—PIK3CA—ovarian cancer	4.62e-06	4.64e-05	CbGpPWpGaD
Naloxone—CREB1—Signaling Pathways—MMP9—ovarian cancer	4.62e-06	4.63e-05	CbGpPWpGaD
Naloxone—OPRD1—Signaling Pathways—MMP9—ovarian cancer	4.6e-06	4.62e-05	CbGpPWpGaD
Naloxone—CREB1—Signaling Pathways—PTEN—ovarian cancer	4.59e-06	4.61e-05	CbGpPWpGaD
Naloxone—ALB—Hemostasis—MAPK3—ovarian cancer	4.58e-06	4.59e-05	CbGpPWpGaD
Naloxone—OPRD1—Signaling Pathways—PTEN—ovarian cancer	4.58e-06	4.59e-05	CbGpPWpGaD
Naloxone—CYP2C8—Metabolism—ABCB1—ovarian cancer	4.58e-06	4.59e-05	CbGpPWpGaD
Naloxone—ALB—Metabolism—ABCB1—ovarian cancer	4.55e-06	4.56e-05	CbGpPWpGaD
Naloxone—ESR1—Signaling Pathways—APC—ovarian cancer	4.54e-06	4.56e-05	CbGpPWpGaD
Naloxone—ESR1—Signaling Pathways—PIK3CG—ovarian cancer	4.54e-06	4.56e-05	CbGpPWpGaD
Naloxone—OPRM1—Signaling Pathways—PIK3CD—ovarian cancer	4.5e-06	4.52e-05	CbGpPWpGaD
Naloxone—CYP2C8—Metabolism—TYMS—ovarian cancer	4.49e-06	4.51e-05	CbGpPWpGaD
Naloxone—CREB1—Signaling by GPCR—AKT1—ovarian cancer	4.48e-06	4.49e-05	CbGpPWpGaD
Naloxone—ALB—Metabolism—TYMS—ovarian cancer	4.47e-06	4.48e-05	CbGpPWpGaD
Naloxone—OPRD1—Signaling by GPCR—AKT1—ovarian cancer	4.46e-06	4.48e-05	CbGpPWpGaD
Naloxone—OPRK1—Signaling Pathways—CXCL8—ovarian cancer	4.46e-06	4.48e-05	CbGpPWpGaD
Naloxone—OPRM1—GPCR downstream signaling—PIK3CA—ovarian cancer	4.46e-06	4.47e-05	CbGpPWpGaD
Naloxone—SLCO1A2—Metabolism—PTEN—ovarian cancer	4.44e-06	4.46e-05	CbGpPWpGaD
Naloxone—CREB1—Immune System—IL6—ovarian cancer	4.44e-06	4.45e-05	CbGpPWpGaD
Naloxone—OPRK1—Signaling by GPCR—HRAS—ovarian cancer	4.43e-06	4.45e-05	CbGpPWpGaD
Naloxone—OPRM1—Signaling by GPCR—KRAS—ovarian cancer	4.41e-06	4.42e-05	CbGpPWpGaD
Naloxone—OPRK1—Signaling Pathways—CDKN1B—ovarian cancer	4.36e-06	4.37e-05	CbGpPWpGaD
Naloxone—ALB—Hemostasis—MAPK1—ovarian cancer	4.35e-06	4.37e-05	CbGpPWpGaD
Naloxone—OPRK1—GPCR downstream signaling—AKT1—ovarian cancer	4.31e-06	4.32e-05	CbGpPWpGaD
Naloxone—ABCB1—Metabolism—PPP2R1A—ovarian cancer	4.29e-06	4.31e-05	CbGpPWpGaD
Naloxone—CREB1—Disease—HRAS—ovarian cancer	4.28e-06	4.29e-05	CbGpPWpGaD
Naloxone—OPRK1—Signaling Pathways—CASP3—ovarian cancer	4.27e-06	4.28e-05	CbGpPWpGaD
Naloxone—OPRK1—Signaling Pathways—IL2—ovarian cancer	4.26e-06	4.28e-05	CbGpPWpGaD
Naloxone—OPRK1—Signaling by GPCR—IL6—ovarian cancer	4.24e-06	4.26e-05	CbGpPWpGaD
Naloxone—OPRK1—Signaling Pathways—CCND1—ovarian cancer	4.16e-06	4.17e-05	CbGpPWpGaD
Naloxone—CREB1—Signaling Pathways—VEGFA—ovarian cancer	4.15e-06	4.16e-05	CbGpPWpGaD
Naloxone—OPRD1—Signaling Pathways—VEGFA—ovarian cancer	4.13e-06	4.15e-05	CbGpPWpGaD
Naloxone—OPRK1—Signaling Pathways—CTNNB1—ovarian cancer	4.12e-06	4.13e-05	CbGpPWpGaD
Naloxone—ALB—Hemostasis—KRAS—ovarian cancer	4.11e-06	4.13e-05	CbGpPWpGaD
Naloxone—CREB1—Signaling Pathways—STAT3—ovarian cancer	4.11e-06	4.12e-05	CbGpPWpGaD
Naloxone—CREB1—Signaling Pathways—NRAS—ovarian cancer	4.1e-06	4.11e-05	CbGpPWpGaD
Naloxone—CREB1—Disease—IL6—ovarian cancer	4.1e-06	4.11e-05	CbGpPWpGaD
Naloxone—OPRD1—Signaling Pathways—STAT3—ovarian cancer	4.09e-06	4.11e-05	CbGpPWpGaD
Naloxone—CREB1—Immune System—AKT1—ovarian cancer	4.09e-06	4.11e-05	CbGpPWpGaD
Naloxone—OPRD1—Signaling Pathways—NRAS—ovarian cancer	4.08e-06	4.1e-05	CbGpPWpGaD
Naloxone—OPRM1—Signaling by GPCR—PIK3CA—ovarian cancer	4.05e-06	4.06e-05	CbGpPWpGaD
Naloxone—OPRK1—Signaling Pathways—MMP9—ovarian cancer	4.04e-06	4.05e-05	CbGpPWpGaD
Naloxone—CYP3A4—Metabolism—YAP1—ovarian cancer	4.02e-06	4.03e-05	CbGpPWpGaD
Naloxone—OPRK1—Signaling Pathways—PTEN—ovarian cancer	4.01e-06	4.03e-05	CbGpPWpGaD
Naloxone—ESR1—Signaling Pathways—PIK3CD—ovarian cancer	3.99e-06	4e-05	CbGpPWpGaD
Naloxone—OPRM1—Signaling Pathways—ERBB2—ovarian cancer	3.98e-06	3.99e-05	CbGpPWpGaD
Naloxone—ESR1—Gene Expression—MAPK3—ovarian cancer	3.95e-06	3.96e-05	CbGpPWpGaD
Naloxone—OPRM1—Signaling Pathways—MTOR—ovarian cancer	3.92e-06	3.94e-05	CbGpPWpGaD
Naloxone—OPRM1—Signaling Pathways—PIK3CB—ovarian cancer	3.92e-06	3.94e-05	CbGpPWpGaD
Naloxone—CREB1—Signaling Pathways—MAPK3—ovarian cancer	3.92e-06	3.93e-05	CbGpPWpGaD
Naloxone—ABCB1—Metabolism—TYMS—ovarian cancer	3.91e-06	3.93e-05	CbGpPWpGaD
Naloxone—OPRK1—Signaling by GPCR—AKT1—ovarian cancer	3.91e-06	3.93e-05	CbGpPWpGaD
Naloxone—OPRD1—Signaling Pathways—MAPK3—ovarian cancer	3.91e-06	3.92e-05	CbGpPWpGaD
Naloxone—ESR1—Gene Expression—MYC—ovarian cancer	3.84e-06	3.86e-05	CbGpPWpGaD
Naloxone—CREB1—Signaling Pathways—MYC—ovarian cancer	3.81e-06	3.83e-05	CbGpPWpGaD
Naloxone—OPRD1—Signaling Pathways—MYC—ovarian cancer	3.8e-06	3.81e-05	CbGpPWpGaD
Naloxone—ALB—Hemostasis—PIK3CA—ovarian cancer	3.78e-06	3.79e-05	CbGpPWpGaD
Naloxone—CREB1—Disease—AKT1—ovarian cancer	3.78e-06	3.79e-05	CbGpPWpGaD
Naloxone—OPRM1—Signaling Pathways—CXCL8—ovarian cancer	3.77e-06	3.78e-05	CbGpPWpGaD
Naloxone—OPRM1—Signaling by GPCR—HRAS—ovarian cancer	3.75e-06	3.76e-05	CbGpPWpGaD
Naloxone—CREB1—Signaling Pathways—MAPK1—ovarian cancer	3.73e-06	3.74e-05	CbGpPWpGaD
Naloxone—CREB1—Signaling Pathways—EGFR—ovarian cancer	3.73e-06	3.74e-05	CbGpPWpGaD
Naloxone—OPRD1—Signaling Pathways—MAPK1—ovarian cancer	3.72e-06	3.73e-05	CbGpPWpGaD
Naloxone—OPRD1—Signaling Pathways—EGFR—ovarian cancer	3.72e-06	3.73e-05	CbGpPWpGaD
Naloxone—OPRM1—Signaling Pathways—CDKN1B—ovarian cancer	3.68e-06	3.69e-05	CbGpPWpGaD
Naloxone—ALB—Hemostasis—TP53—ovarian cancer	3.66e-06	3.67e-05	CbGpPWpGaD
Naloxone—OPRM1—GPCR downstream signaling—AKT1—ovarian cancer	3.64e-06	3.65e-05	CbGpPWpGaD
Naloxone—OPRK1—Signaling Pathways—VEGFA—ovarian cancer	3.62e-06	3.64e-05	CbGpPWpGaD
Naloxone—CYP2C8—Metabolism—CAV1—ovarian cancer	3.62e-06	3.63e-05	CbGpPWpGaD
Naloxone—OPRM1—Signaling Pathways—CASP3—ovarian cancer	3.61e-06	3.62e-05	CbGpPWpGaD
Naloxone—OPRM1—Signaling Pathways—IL2—ovarian cancer	3.6e-06	3.62e-05	CbGpPWpGaD
Naloxone—ALB—Metabolism—CAV1—ovarian cancer	3.6e-06	3.61e-05	CbGpPWpGaD
Naloxone—OPRK1—Signaling Pathways—STAT3—ovarian cancer	3.59e-06	3.6e-05	CbGpPWpGaD
Naloxone—OPRM1—Signaling by GPCR—IL6—ovarian cancer	3.59e-06	3.6e-05	CbGpPWpGaD
Naloxone—OPRK1—Signaling Pathways—NRAS—ovarian cancer	3.58e-06	3.59e-05	CbGpPWpGaD
Naloxone—ESR1—Signaling Pathways—ERBB2—ovarian cancer	3.53e-06	3.54e-05	CbGpPWpGaD
Naloxone—CREB1—Signaling Pathways—KRAS—ovarian cancer	3.52e-06	3.54e-05	CbGpPWpGaD
Naloxone—OPRD1—Signaling Pathways—KRAS—ovarian cancer	3.51e-06	3.53e-05	CbGpPWpGaD
Naloxone—OPRM1—Signaling Pathways—CCND1—ovarian cancer	3.51e-06	3.52e-05	CbGpPWpGaD
Naloxone—ALB—Hemostasis—HRAS—ovarian cancer	3.5e-06	3.51e-05	CbGpPWpGaD
Naloxone—ESR1—Signaling Pathways—MTOR—ovarian cancer	3.48e-06	3.49e-05	CbGpPWpGaD
Naloxone—ESR1—Signaling Pathways—PIK3CB—ovarian cancer	3.48e-06	3.49e-05	CbGpPWpGaD
Naloxone—OPRM1—Signaling Pathways—CTNNB1—ovarian cancer	3.48e-06	3.49e-05	CbGpPWpGaD
Naloxone—CYP2C8—Metabolism of lipids and lipoproteins—PIK3CA—ovarian cancer	3.46e-06	3.47e-05	CbGpPWpGaD
Naloxone—ALB—Metabolism of lipids and lipoproteins—PIK3CA—ovarian cancer	3.44e-06	3.45e-05	CbGpPWpGaD
Naloxone—OPRK1—Signaling Pathways—MAPK3—ovarian cancer	3.43e-06	3.44e-05	CbGpPWpGaD
Naloxone—OPRM1—Signaling Pathways—MMP9—ovarian cancer	3.41e-06	3.42e-05	CbGpPWpGaD
Naloxone—OPRM1—Signaling Pathways—PTEN—ovarian cancer	3.39e-06	3.4e-05	CbGpPWpGaD
Naloxone—ESR1—Signaling Pathways—CXCL8—ovarian cancer	3.34e-06	3.35e-05	CbGpPWpGaD
Naloxone—OPRK1—Signaling Pathways—MYC—ovarian cancer	3.33e-06	3.35e-05	CbGpPWpGaD
Naloxone—OPRM1—Signaling by GPCR—AKT1—ovarian cancer	3.31e-06	3.32e-05	CbGpPWpGaD
Naloxone—CYP2C8—Metabolism—PIK3CG—ovarian cancer	3.3e-06	3.31e-05	CbGpPWpGaD
Naloxone—ALB—Metabolism—PIK3CG—ovarian cancer	3.28e-06	3.29e-05	CbGpPWpGaD
Naloxone—CYP3A4—Metabolism—FASN—ovarian cancer	3.27e-06	3.28e-05	CbGpPWpGaD
Naloxone—ESR1—Signaling Pathways—CDKN1B—ovarian cancer	3.27e-06	3.28e-05	CbGpPWpGaD
Naloxone—OPRK1—Signaling Pathways—MAPK1—ovarian cancer	3.26e-06	3.27e-05	CbGpPWpGaD
Naloxone—OPRK1—Signaling Pathways—EGFR—ovarian cancer	3.26e-06	3.27e-05	CbGpPWpGaD
Naloxone—CREB1—Signaling Pathways—PIK3CA—ovarian cancer	3.24e-06	3.25e-05	CbGpPWpGaD
Naloxone—OPRD1—Signaling Pathways—PIK3CA—ovarian cancer	3.23e-06	3.24e-05	CbGpPWpGaD
Naloxone—CYP3A4—Metabolism—SLC5A5—ovarian cancer	3.22e-06	3.23e-05	CbGpPWpGaD
Naloxone—ESR1—Signaling Pathways—CASP3—ovarian cancer	3.2e-06	3.21e-05	CbGpPWpGaD
Naloxone—ESR1—Signaling Pathways—IL2—ovarian cancer	3.2e-06	3.21e-05	CbGpPWpGaD
Naloxone—ABCB1—Metabolism—CAV1—ovarian cancer	3.15e-06	3.16e-05	CbGpPWpGaD
Naloxone—SLCO1A2—Metabolism—PIK3CA—ovarian cancer	3.14e-06	3.15e-05	CbGpPWpGaD
Naloxone—CREB1—Signaling Pathways—TP53—ovarian cancer	3.13e-06	3.14e-05	CbGpPWpGaD
Naloxone—OPRD1—Signaling Pathways—TP53—ovarian cancer	3.12e-06	3.13e-05	CbGpPWpGaD
Naloxone—ESR1—Signaling Pathways—CCND1—ovarian cancer	3.12e-06	3.13e-05	CbGpPWpGaD
Naloxone—CYP3A4—Metabolism—SLC2A1—ovarian cancer	3.11e-06	3.12e-05	CbGpPWpGaD
Naloxone—ALB—Hemostasis—AKT1—ovarian cancer	3.09e-06	3.1e-05	CbGpPWpGaD
Naloxone—ESR1—Signaling Pathways—CTNNB1—ovarian cancer	3.08e-06	3.09e-05	CbGpPWpGaD
Naloxone—OPRK1—Signaling Pathways—KRAS—ovarian cancer	3.08e-06	3.09e-05	CbGpPWpGaD
Naloxone—OPRM1—Signaling Pathways—VEGFA—ovarian cancer	3.06e-06	3.07e-05	CbGpPWpGaD
Naloxone—OPRM1—Signaling Pathways—STAT3—ovarian cancer	3.03e-06	3.04e-05	CbGpPWpGaD
Naloxone—OPRM1—Signaling Pathways—NRAS—ovarian cancer	3.03e-06	3.04e-05	CbGpPWpGaD
Naloxone—ESR1—Signaling Pathways—MMP9—ovarian cancer	3.02e-06	3.03e-05	CbGpPWpGaD
Naloxone—ESR1—Signaling Pathways—PTEN—ovarian cancer	3.01e-06	3.02e-05	CbGpPWpGaD
Naloxone—CREB1—Signaling Pathways—HRAS—ovarian cancer	3e-06	3.01e-05	CbGpPWpGaD
Naloxone—OPRD1—Signaling Pathways—HRAS—ovarian cancer	2.99e-06	3e-05	CbGpPWpGaD
Naloxone—CYP3A4—Metabolism—CYP1B1—ovarian cancer	2.98e-06	2.99e-05	CbGpPWpGaD
Naloxone—CYP2C8—Metabolism—PIK3CD—ovarian cancer	2.9e-06	2.91e-05	CbGpPWpGaD
Naloxone—OPRM1—Signaling Pathways—MAPK3—ovarian cancer	2.9e-06	2.91e-05	CbGpPWpGaD
Naloxone—ALB—Metabolism—PIK3CD—ovarian cancer	2.88e-06	2.89e-05	CbGpPWpGaD
Naloxone—ABCB1—Metabolism—PIK3CG—ovarian cancer	2.87e-06	2.88e-05	CbGpPWpGaD
Naloxone—CREB1—Signaling Pathways—IL6—ovarian cancer	2.87e-06	2.88e-05	CbGpPWpGaD
Naloxone—OPRD1—Signaling Pathways—IL6—ovarian cancer	2.86e-06	2.87e-05	CbGpPWpGaD
Naloxone—OPRK1—Signaling Pathways—PIK3CA—ovarian cancer	2.83e-06	2.84e-05	CbGpPWpGaD
Naloxone—OPRM1—Signaling Pathways—MYC—ovarian cancer	2.82e-06	2.83e-05	CbGpPWpGaD
Naloxone—OPRM1—Signaling Pathways—MAPK1—ovarian cancer	2.76e-06	2.77e-05	CbGpPWpGaD
Naloxone—OPRM1—Signaling Pathways—EGFR—ovarian cancer	2.76e-06	2.77e-05	CbGpPWpGaD
Naloxone—OPRK1—Signaling Pathways—TP53—ovarian cancer	2.74e-06	2.75e-05	CbGpPWpGaD
Naloxone—ESR1—Signaling Pathways—VEGFA—ovarian cancer	2.72e-06	2.72e-05	CbGpPWpGaD
Naloxone—ESR1—Signaling Pathways—STAT3—ovarian cancer	2.69e-06	2.7e-05	CbGpPWpGaD
Naloxone—ESR1—Signaling Pathways—NRAS—ovarian cancer	2.68e-06	2.69e-05	CbGpPWpGaD
Naloxone—ESR1—Gene Expression—AKT1—ovarian cancer	2.67e-06	2.67e-05	CbGpPWpGaD
Naloxone—CREB1—Signaling Pathways—AKT1—ovarian cancer	2.65e-06	2.65e-05	CbGpPWpGaD
Naloxone—CYP3A4—Metabolism—PPP2R1A—ovarian cancer	2.64e-06	2.65e-05	CbGpPWpGaD
Naloxone—OPRD1—Signaling Pathways—AKT1—ovarian cancer	2.64e-06	2.65e-05	CbGpPWpGaD
Naloxone—OPRK1—Signaling Pathways—HRAS—ovarian cancer	2.62e-06	2.63e-05	CbGpPWpGaD
Naloxone—OPRM1—Signaling Pathways—KRAS—ovarian cancer	2.6e-06	2.61e-05	CbGpPWpGaD
Naloxone—ESR1—Signaling Pathways—MAPK3—ovarian cancer	2.57e-06	2.58e-05	CbGpPWpGaD
Naloxone—SLCO1A2—Metabolism—AKT1—ovarian cancer	2.56e-06	2.57e-05	CbGpPWpGaD
Naloxone—CYP2C8—Metabolism—PIK3CB—ovarian cancer	2.53e-06	2.54e-05	CbGpPWpGaD
Naloxone—ABCB1—Metabolism—PIK3CD—ovarian cancer	2.53e-06	2.53e-05	CbGpPWpGaD
Naloxone—ALB—Metabolism—PIK3CB—ovarian cancer	2.51e-06	2.52e-05	CbGpPWpGaD
Naloxone—OPRK1—Signaling Pathways—IL6—ovarian cancer	2.51e-06	2.51e-05	CbGpPWpGaD
Naloxone—ESR1—Signaling Pathways—MYC—ovarian cancer	2.5e-06	2.51e-05	CbGpPWpGaD
Naloxone—CYP3A4—Metabolism—ABCB1—ovarian cancer	2.46e-06	2.46e-05	CbGpPWpGaD
Naloxone—ESR1—Signaling Pathways—MAPK1—ovarian cancer	2.44e-06	2.45e-05	CbGpPWpGaD
Naloxone—ESR1—Signaling Pathways—EGFR—ovarian cancer	2.44e-06	2.45e-05	CbGpPWpGaD
Naloxone—CYP3A4—Metabolism—TYMS—ovarian cancer	2.41e-06	2.42e-05	CbGpPWpGaD
Naloxone—OPRM1—Signaling Pathways—PIK3CA—ovarian cancer	2.39e-06	2.4e-05	CbGpPWpGaD
Naloxone—OPRM1—Signaling Pathways—TP53—ovarian cancer	2.31e-06	2.32e-05	CbGpPWpGaD
Naloxone—OPRK1—Signaling Pathways—AKT1—ovarian cancer	2.31e-06	2.32e-05	CbGpPWpGaD
Naloxone—ESR1—Signaling Pathways—KRAS—ovarian cancer	2.31e-06	2.32e-05	CbGpPWpGaD
Naloxone—OPRM1—Signaling Pathways—HRAS—ovarian cancer	2.21e-06	2.22e-05	CbGpPWpGaD
Naloxone—ABCB1—Metabolism—PIK3CB—ovarian cancer	2.2e-06	2.21e-05	CbGpPWpGaD
Naloxone—CYP2C8—Metabolism—PTEN—ovarian cancer	2.18e-06	2.19e-05	CbGpPWpGaD
Naloxone—ALB—Metabolism—PTEN—ovarian cancer	2.17e-06	2.18e-05	CbGpPWpGaD
Naloxone—ESR1—Signaling Pathways—PIK3CA—ovarian cancer	2.12e-06	2.13e-05	CbGpPWpGaD
Naloxone—OPRM1—Signaling Pathways—IL6—ovarian cancer	2.12e-06	2.13e-05	CbGpPWpGaD
Naloxone—ESR1—Signaling Pathways—TP53—ovarian cancer	2.05e-06	2.06e-05	CbGpPWpGaD
Naloxone—ESR1—Signaling Pathways—HRAS—ovarian cancer	1.96e-06	1.97e-05	CbGpPWpGaD
Naloxone—OPRM1—Signaling Pathways—AKT1—ovarian cancer	1.95e-06	1.96e-05	CbGpPWpGaD
Naloxone—CYP3A4—Metabolism—CAV1—ovarian cancer	1.94e-06	1.95e-05	CbGpPWpGaD
Naloxone—ABCB1—Metabolism—PTEN—ovarian cancer	1.9e-06	1.91e-05	CbGpPWpGaD
Naloxone—ESR1—Signaling Pathways—IL6—ovarian cancer	1.88e-06	1.88e-05	CbGpPWpGaD
Naloxone—CYP3A4—Metabolism—PIK3CG—ovarian cancer	1.77e-06	1.78e-05	CbGpPWpGaD
Naloxone—ESR1—Signaling Pathways—AKT1—ovarian cancer	1.73e-06	1.74e-05	CbGpPWpGaD
Naloxone—CYP3A4—Metabolism—PIK3CD—ovarian cancer	1.56e-06	1.56e-05	CbGpPWpGaD
Naloxone—CYP2C8—Metabolism—PIK3CA—ovarian cancer	1.54e-06	1.55e-05	CbGpPWpGaD
Naloxone—ALB—Metabolism—PIK3CA—ovarian cancer	1.53e-06	1.54e-05	CbGpPWpGaD
Naloxone—CYP3A4—Metabolism—PIK3CB—ovarian cancer	1.36e-06	1.36e-05	CbGpPWpGaD
Naloxone—ABCB1—Metabolism—PIK3CA—ovarian cancer	1.34e-06	1.35e-05	CbGpPWpGaD
Naloxone—CYP2C8—Metabolism—AKT1—ovarian cancer	1.26e-06	1.26e-05	CbGpPWpGaD
Naloxone—ALB—Metabolism—AKT1—ovarian cancer	1.25e-06	1.26e-05	CbGpPWpGaD
Naloxone—CYP3A4—Metabolism—PTEN—ovarian cancer	1.17e-06	1.18e-05	CbGpPWpGaD
Naloxone—ABCB1—Metabolism—AKT1—ovarian cancer	1.1e-06	1.1e-05	CbGpPWpGaD
Naloxone—CYP3A4—Metabolism—PIK3CA—ovarian cancer	8.27e-07	8.3e-06	CbGpPWpGaD
Naloxone—CYP3A4—Metabolism—AKT1—ovarian cancer	6.76e-07	6.78e-06	CbGpPWpGaD
